Christopher Richard
- SEC CIK
- 0001271244
No open-market purchases or sales filed in the past year.
Current role at each company
- LEXX Lexaria Bioscience Corp.Chief Executive Officeras of Jul 30, 2025
- NVIV Invivo Therapeutics Holdings Corp.Chief Financial Officeras of Nov 21, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Christopher Richard as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
LEXX Lexaria Bioscience Corp.
Chief Executive Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2025 (view filing) | Jul 29 | 1 day | Christopher RichardChief Executive Officer | PPurchase | +15.0K | $0.91 | +$13.7K | +30.0%65.0K after | |
| Dec 3, 2024 (view filing) | Dec 2-3 | 1 day | Christopher RichardChief Executive Officer | PPurchase | +50.0K | $2.36 | +$118.2K | New position50.0K after | 2 lots |